Wockhardt Limited

Ranbaxy Laboratories, Inc.

Wockhardt Research Centre

Jain, Girish Kumar

Dabre, Rahul

Gundu, Ramakant

Ujjainkar, Amol

Balla Pattabhi, Srinivas

Khan, Abdul Rehman

Murali, Narayanan

Girish Kumar Jain

Munish Talwar

Prashant Mandaogade

Premchand Dalichandji Nakhat

Ritesh Kapoor

Ramakant Kashinath Gundu

Manoj Mashalkar

Narayanan Murali

Rahul Dabre

Chandrashekhar Kandi

Amit Gupta

Sanjay Mate

Venkatesh Madhavacharya Joshi

Himadri Sen

Saurabh Srivastava

Sudhir Goswami

Vinayak Dinkar Kadam

Mahesh Rameshwar Kalantri

Asif Mohammad

Mandar Kodgule

Ashok Rampal

Cyril Estanove

François Pruvost

Yatendra Kumar Gupta

Srikanth Pattipati

Jagdish Arora

Mandar Madhukar Kodgule

Venkataramana Naidu

Himanshu Verma

Abdul Rehman Khan

Roshanlal Sandal

Inderjeetsingh Huda

Amar Agarwal

Vishwanath Nande

Kasturi Roy

Amol Ujjainkar

Srinivas Balla Pattabhi

The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.

Oral pharmaceutical composition of aliphatic amine polymer or salts thereof

There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.

Methods for treating cardiovascular disorders

The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.

Modified release dosage form comprising desvenlafaxine or salts thereof

The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.

Tablet dosage form

The present invention relates to stable pharmaceutical compositions comprising entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts or hydrates thereof. The invention also relates to processes for the preparation of such compositions.

Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa

The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.

Pharmaceutical compositions of duloxetine

There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Extended release pharmaceutical composition of entacapone or salts thereof

The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50&#xae;. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50&#xae;. The invention also relates to methods for preparing such compositions.

Self-emulsifying pharmaceutical compositions of rhein or diacerein

The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.

Pharmaceutical compositions of fenofibrate

The invention relates to liquid pharmaceutical compositions for oral administration comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions.

Oral liquid compositions of rhein or diacerein

The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200&#xae;. The invention also relates to processes for making such compositions.

Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability

The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.

Extended release dosage forms of metoprolol

There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof

Growing community of inventors

Delhi, India

Girish Kumar Jain